Michael S Hofman

43PUBLICATIONS
158CO-AUTHORS
Molecular targetsPredictive and prognostic markersRadiation therapyToxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Jul 02, 2026
Germline CDK12 variants in aggressive prostate cancer.

|Apr 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

|Apr 21, 2026
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.

|Apr 14, 2026
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.

Abdullah Al-Khanaty, David Chen, Jonathan Walbaum

|Apr 14, 2026
From salvage to spotlight: how 2025 transformed PSMA radioligand therapy.

Abdullah Al-Khanaty, Carlos Delgado, Francisco Valencia

|Feb 06, 2026
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.

Aslı D Munzur, Cameron Herberts, Edmond M Kwan

Pageof 8

Frequent Collaborators

15 joint publications

Declan Murphy

8 joint publications

Arun Azad

7 joint publications

Nathan Lawrentschuk

6 joint publications

Louise Emmett